Last $2.96 USD
Change Today +0.11 / 3.86%
Volume 18.9K
REPH On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

recro pharma inc (REPH) Snapshot

Open
$2.83
Previous Close
$2.85
Day High
$2.97
Day Low
$2.80
52 Week High
03/20/14 - $9.88
52 Week Low
09/29/14 - $2.71
Market Cap
22.8M
Average Volume 10 Days
33.2K
EPS TTM
--
Shares Outstanding
7.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RECRO PHARMA INC (REPH)

Related News

No related news articles were found.

recro pharma inc (REPH) Related Businessweek News

No Related Businessweek News Found

recro pharma inc (REPH) Details

Recro Pharma, Inc., a clinical stage specialty pharmaceutical company, is engaged in the development of various non-opioid therapeutics for the treatment of pain and related conditions in the United States. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. It has a license agreement with Orion Corporation for the development and commercialization of Dex and Fado. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

recro pharma inc (REPH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $125.0K
Compensation as of Fiscal Year 2013.

recro pharma inc (REPH) Key Developments

Recro Pharma, Inc. Provides Clinical Strategy Update of Interim Analysis for Phase IIb Clinical Trial of Dex-In

Recro Pharma, Inc. announced a clinical strategy update following findings from a prespecified interim analysis conducted on the initial half of patients who completed enrollment in the Company's REC-13-012 trial. The trial is a double blind, placebo-controlled study of intranasal dexmedetomidine, Dex-IN, in the treatment of acute post-operative pain following bunionectomy surgery on Post Op Day 0. While analgesia and a reduction in opioid use were observed in a subset of patients, the study is not expected to reach statistical significance in its current design. As a result, the company plans to close this study and launch a revised study starting in fourth quarter of 2014. The company will evaluate Dex-IN 50 mcg versus placebo in management of post-op pain starting Post Op Day 1 after bunionectomy surgery. Note that there were no serious adverse events observed in the REC-13-012 trial. The interim analysis was based on the primary endpoint, SPID48 (summed pain intensity difference over 48 hours). This preplanned interim analysis was designed to allow for possible sample size adjustment. The results of the interim analysis (n=68, approximately 22 patients per group) revealed that the efficacy of Dex-IN as a stand alone drug was not sufficient to manage severe pain in bunionectomy on post operative day zero, Post Op Day 0. As a result, increased sample size is unlikely to be an effective modification of the trial. In the interim analysis, the company observed in patients with baseline pain intensity scores of <= 6 (N=34) that pain was more effectively managed on Post Op Day 0, as seen in the separation of scores between Dex-IN 50 mcg and Placebo. In addition, based on an understanding of the trajectory of pain, it is recognized that pain on Post Op Day 0 is generally escalating, while pain on Post Op Day 1, or the day after surgery, is generally stable or declining. Based on the input from the company's advisors, the results of the interim analysis and subset analyses, the information suggests that a post-operative pain management study in patients who initiate study treatment on Post Op Day 1 would be more effective than the current study design. The company expects such a study would enroll between 150 and 200 subjects, and is targeting initiation in fourth quarter of 2014, with top line results estimated to be available mid-year 2015.

Recro Pharma, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 11:25 AM

Recro Pharma, Inc. Presents at Aegis Capital 2014 Healthcare & Technology Conference, Sep-12-2014 11:25 AM. Venue: The Encore at Wynn Las Vegas, 3121 Las Vegas Blvd. South, Las Vegas, NV 89109, United States. Speakers: Geraldine A. Henwood, Chief Executive Officer, President and Director.

Recro Pharma, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Recro Pharma, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported a net loss applicable to common shareholders of $2,793,528, or $0.36 per share basic and diluted compared to a net loss of $773,909, or $4.97 per share basic and diluted for the comparable period in 2013. Interest income was $2,276 against $17 for the same period a year ago. The second quarter of 2013 includes accretion of Recro Pharma's redeemable convertible preferred stock. For the six months, the company reported a net loss applicable to common shareholders of $9,209,915, or $1.94 per share basic and diluted compared to a net loss of $1,286,995, or $8.27 per share basic and diluted for the comparable period in 2013. Interest income was $2,491 against $20 for the same period a year ago. The six months ended June 30, 2014 includes a $4.1 million non-cash beneficial conversion charge related to the conversion of 8% Convertible Promissory Notes upon the closing of initial public offering in March 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REPH:US $2.96 USD +0.11

REPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for REPH.
View Industry Companies
 

Industry Analysis

REPH

Industry Average

Valuation REPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECRO PHARMA INC, please visit www.recropharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.